The tracking of antibodies in Ebola survivors suggests they wax and wane, which could make vaccine booster shots necessary.
Guinea is having its first Ebola outbreak since 2016, when West Africa experienced the biggest outbreak ever seen. Could the vaccine that contained previous outbreaks soon be redeployed?
As a Gavi-funded emergency stockpile of Ebola vaccines becomes accessible, we look at the ultra-cold chain equipment used to keep these vaccines at the right temperature.
COVID-19 vaccines are set to become the quickest vaccines in history to go from initial trials to rollout, but what lessons can we learn from its speedy predecessor: the Ebola vaccine?
Like patients with long COVID, some Ebola survivors have lingering symptoms which can make it difficult to work or function in everyday life. Dr Janet Scott has been studying these survivors, and now also has her sights on COVID-19. She tells us what she’s learned so far.
Scientists have been racing to develop COVID-19 vaccines that could reach millions, yet many of the studies have surprisingly small sample sizes drawn from the clinical trials. Does that matter?
Here’s how Gavi helps lower-income countries get the new vaccines and products they need to address urgent threats to public health – from cholera and COVID-19, to Ebola and pneumonia.
Snapshots from DRC, India and Zambia illustrate country ownership and progress in the fights against Ebola, polio and HPV.
The misinformation surrounding COVID-19 in the Democratic Repubic of the Congo isn’t new – public health officials have seen rumours and myths circulate with Ebola. Here’s how they are tackling them.